Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
NCT ID: NCT05561374
Last Updated: 2024-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
16 participants
INTERVENTIONAL
2023-04-17
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low-dose OKN-007, two times a day (BID)
Dose Escalation Cohort 1
Low-dose OKN-007, BID
Participants will be administered low doses of oral OKN-007 two times a day daily in 28-day cycles.
Low-dose OKN-007, three times a day (TID)
Dose Escalation Cohort 2
Low-dose OKN-007, TID
Participants will be administered low doses of oral OKN-007 three times a day daily in 28-day cycles.
Mid-dose OKN-007, three times a day (TID)
Dose Escalation Cohort 3
Mid-dose OKN-007, TID
Participants will be administered mid doses of oral OKN-007 three times a day daily in 28-day cycles.
High-dose OKN-007, three times a day (TID)
Dose Escalation Cohort 4
High-dose OKN-007, TID
Participants will be administered high doses of oral OKN-007 three times a day daily in 28-day cycles.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low-dose OKN-007, BID
Participants will be administered low doses of oral OKN-007 two times a day daily in 28-day cycles.
Low-dose OKN-007, TID
Participants will be administered low doses of oral OKN-007 three times a day daily in 28-day cycles.
Mid-dose OKN-007, TID
Participants will be administered mid doses of oral OKN-007 three times a day daily in 28-day cycles.
High-dose OKN-007, TID
Participants will be administered high doses of oral OKN-007 three times a day daily in 28-day cycles.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Progressive or recurrent gliomas documented by magnetic resonance imaging (MRI) no earlier than 180 days after first surgery for gliomas and no earlier than 90 days after completion of radiotherapy (applies to patients with first progression/recurrence only).
3. Patients must have medical records available documenting known histology or molecular and genetic information resulting from prior analyses, or tumor tissue samples available from prior glioma surgery or open biopsy for correlative research.
4. For patients with unresected recurrent tumor, unequivocal radiographic evidence of tumor progression by MRI as per the RANO criteria within 28 days prior to the first dose. These patients must have at least one measurable lesion per RANO.
5. No more than two prior lines of therapy for high-grade glioma (WHO Grade 3 or 4). The first-line therapy must include radiotherapy (minimum of 50 Gy; 34 Gy in elderly patients) with concomitant or adjuvant standard chemotherapy (temozolomide (TMZ), or procarbazine, lomustine and vincristine in patients with anaplastic oligodendroglioma).
6. Eastern Cooperative Oncology Group (ECOG) performance status \<2.
7. Full recovery (grade ≤1) from the toxic effects of any earlier intervention and a minimum of 28 days from the last administration of any investigational agent that has not received regulatory approval for any indication at the time of registration.
8. Adequate renal, liver and bone marrow function without packed red blood cell/platelet transfusions within 4 weeks of the date of lab test during screening:
* Leukocytes ≥3.0 × 10\^9/L
* Absolute neutrophil count (ANC) ≥1.5 × 10\^9/L
* Platelets ≥100 × 10\^9/L
* Hemoglobin ≥ 9.0 g/dL
* Total bilirubin ≤1.5 × upper limit of normal (ULN), unless documented Gilbert's syndrome.
* Aspartate transaminase/alanine transaminase ≤2.5 × ULN
* Creatinine clearance ≥60 mL/min calculated as per Cockcroft-Gault equation.
9. Patients must be ≥18 years of age.
10. Life expectancy (as assessed by the Investigator) at least three months.
11. Patients must not have significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea, or inability to swallow oral medications.
12. Have provided written informed consent.
13. Patients must be willing to have multiple blood draws for PK analysis.
14. Female patients, of childbearing potential, must have a negative serum pregnancy test within 7 days prior to study treatment initiation and agree to use adequate contraception or practice sexual abstinence as the preferred and usual lifestyle of the patient during the study and for up to 120 days (4 months) after the last dose of study treatment.
15. Male patients with female partners of childbearing potential must, even if surgically sterilized, agree to practice effective barrier contraception and practice true abstinence.
16. Human immunodeficiency virus infected patients on effective antiretroviral therapy with undetectable viral load within 6 months prior to study registration are eligible for this trial.
Exclusion Criteria
2. Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study registration.
3. Have received chemotherapeutic agents (including TMZ) within 28 days or within 5 half-lives for non-cytotoxic agents (whichever is shorter) of study registration.
4. Serious concomitant systemic disorders, for example, abnormal electrocardiogram (ECG) indicative of cardiac disease (patients with Fridericia-corrected QT interval \[QTcF\] \>480 msec.
5. Patients with abnormal sodium, potassium, or creatinine levels grade ≥2.
6. Inability to comply with protocol or study procedures.
7. Women who are pregnant or breastfeeding.
8. Patients who have received bevacizumab for recurrent glioblastoma or are planning to initiate treatment with bevacizumab for tumor necrosis.
9. Patients completing radiotherapy treatment less than 2 weeks prior to planned study treatment initiation.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oblato, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Providence Saint John's Cancer Institute
Santa Monica, California, United States
Norton Healthcare
Louisville, Kentucky, United States
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
The University of Oklahoma Health Sciences Center, Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OKN-007-OL-RMG-101
Identifier Type: -
Identifier Source: org_study_id